For research use only. Not for therapeutic Use.
NSC16168 is a specific inhibitor of ERCC1-XPF, with an IC50 value of 0.42 μM. NSC16168 inhibits DNA repair and potentiates CDDP efficacy in cancer[1].
NSC16168 (0-50 μM) potentiates cisplatin efficacy in cancer cells[1].
NSC16168 (20 mg/kg, ip, twice daily) exhibits significant anti-tumor activity and potentiates cisplatin antitumor activity in H460 lung cancer xenografts[1].
| Catalog Number | I019133 |
| CAS Number | 6837-93-0 |
| Synonyms | 4-amino-5-(4-methylphenyl)sulfonyloxynaphthalene-2,7-disulfonic acid |
| Molecular Formula | C17H15NO9S3 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H15NO9S3/c1-10-2-4-12(5-3-10)30(25,26)27-16-9-14(29(22,23)24)7-11-6-13(28(19,20)21)8-15(18)17(11)16/h2-9H,18H2,1H3,(H,19,20,21)(H,22,23,24) |
| InChIKey | ZIQWUYNDHGXLIN-UHFFFAOYSA-N |
| SMILES | CC1=CC=C(C=C1)S(=O)(=O)OC2=CC(=CC3=CC(=CC(=C32)N)S(=O)(=O)O)S(=O)(=O)O |
| Reference | [1]. Arora S, et al. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget. 2016 Nov 15;7(46):75104-75117. |
